These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31365534)

  • 1. The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014.
    Moodley R; Suleman F
    PLoS One; 2019; 14(7):e0219690. PubMed ID: 31365534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
    Moodley R; Suleman F
    BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudo-Generics in South Africa: A Price Comparison.
    Bangalee V; Suleman F
    Value Health Reg Issues; 2019 Sep; 19():87-91. PubMed ID: 31357098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the impact of single exit pricing (SEP) on medicine product withdrawal from the private healthcare market in South Africa.
    Naidoo K; Suleman F
    S Afr Med J; 2021 Apr; 111(5):444-447. PubMed ID: 34852886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.
    de Jager H; Suleman F
    Int J Clin Pharm; 2019 Feb; 41(1):81-87. PubMed ID: 30478491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the introduction of mandatory generic substitution in South Africa: private sector sales of generic and originator medicines for chronic diseases.
    Gray AL; Santa-Ana-Tellez Y; J Wirtz V
    Trop Med Int Health; 2016 Dec; 21(12):1504-1512. PubMed ID: 27671539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa.
    Mattila PO; Babar ZU; Suleman F
    BMC Health Serv Res; 2021 Jul; 21(1):661. PubMed ID: 34229693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
    Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
    Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
    Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
    Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
    Wouters OJ; Sandberg DM; Pillay A; Kanavos PG
    Soc Sci Med; 2019 Jan; 220():362-370. PubMed ID: 30513486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
    Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
    PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prices & availability of common medicines at six sites in India using a standard methodology.
    Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
    Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Medicine Prices in New Zealand and 16 European Countries.
    Vogler S; Kilpatrick K; Babar ZU
    Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Availability of generic drugs in the public sector and prices in the private sector in different regions of Brazil].
    Miranda ES; Pinto Cdu B; dos Reis AL; Emmerick IC; Campos MR; Luiza VL; Osorio-de-Castro CG
    Cad Saude Publica; 2009 Oct; 25(10):2147-58. PubMed ID: 19851615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
    Bertoldi AD; Helfer AP; Camargo AL; Tavares NU; Kanavos P
    Global Health; 2012 Mar; 8():6. PubMed ID: 22436555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.